Whooping cough resurgence threatens newborn lives in the U.S

In the United States, whooping cough, or pertussis, has seen a notable resurgence, surpassing the number of cases reported prior to the COVID-19 pandemic. According to a report published on October 3, 2025, in the journal Pediatrics, the increase in cases presents a significant risk to newborns and infants, particularly those aged two months and under. Most infants in this age group who contract the illness require hospitalization due to severe symptoms that can emerge despite the absence of the characteristic 'whoop' sound typically associated with the disease. Instead, infants may experience apnea, or interruptions in breathing, which can pose life-threatening complications. High white blood cell counts, or leukocytosis, may occur as a result, leading to potential misdiagnosis as other serious health conditions, such as cancer. Experts emphasize the importance of awareness among healthcare providers in considering pertussis in cases of elevated white blood cell levels in infants. To address the rising risk, experts advocate for vaccination against pertussis as a vital preventive measure. The Centers for Disease Control and Prevention (CDC) strongly recommends that mothers receive the Tdap vaccine during pregnancy, specifically between 27 and 36 weeks gestation, to help provide their newborns protection during the early vulnerable months of life. Additionally, a comprehensive vaccination schedule for children has been established, recommending doses at 2, 4, and 6 months, as well as booster shots at ages 11 to 12 and catch-up doses through age 18. Beyond vaccinations, early treatment with antibiotics is crucial for mitigating symptoms and controlling the spread of the disease. As the threat of pertussis looms larger, healthcare experts stress the need for widespread vaccination and early recognition of the disease, particularly in infants, to protect against what can be a potentially fatal illness.